|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
|
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets: | ||||||||
| Cash | ||||||||
| Cash in escrow | ||||||||
| Prepaid expenses | ||||||||
| Total Current Assets | ||||||||
| Deferred offering costs | ||||||||
| Cash and Investments held in trust account | ||||||||
| TOTAL ASSETS | ||||||||
| LIABILITIES AND SHAREHOLDERS’ DEFICIT | ||||||||
| Current Liabilities: | ||||||||
| Accrued liabilities | ||||||||
| Due to related party | ||||||||
| Promissory note – related party | ||||||||
| Promissory note | ||||||||
| Other payable | ||||||||
| Total Current Liabilities | ||||||||
| Deferred Underwriting Compensation | ||||||||
| TOTAL LIABILITIES | ||||||||
| Ordinary shares subject to possible redemption, 143,382 and 6,900,000 shares issued and outstanding at redemption value of $11.15 and $10.48 as of September 30, 2025 and December 31, 2024, respectively | ||||||||
| Shareholders’ Deficit: | ||||||||
| Ordinary shares, $0.0001 par value; 500,000,000 shares authorized; 2,063,000 and 2,063,000 shares issued and outstanding (excluding 143,382 and 6,900,000 shares, subject to possible redemption as of September 30, 2025 and December 31, 2024, respectively) | ||||||||
| Additional paid-in capital | ||||||||
| Accumulated Deficit | ||||||||
| Total Shareholders’ Deficit | ||||||||
| TOTAL LIABILITIES AND SHAREHOLDERS’ DEFICIT |
Loading...
